TRK 530

inhibits type II collagen-induced arthritis in mice; a bone density conservation agent; structure in first source

Also Known As:

4-((methylthio)phenylthio)methanebisphosphonate; MPMBP compound; TRK-530; disodium dihydrogen-4-((methylthio) phenylthio) methanebisphosphonate; disodium dihydrogen-4-((methylthio)phenylthio)methanebisphosphonate; disodium;hydroxy-((hydroxy(oxido)phosphoryl)-(4-methylsulfanylphenyl)sulfanylmethyl)phosphinate

Networked: 8 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Organophosphorus Compounds: 300
  - Organophosphonates: 424
    - Diphosphonates: 11565
      - TRK 530: 8

Experts

1.	Shinoda, Hisashi: 2 articles (04/2008 - 04/2004)
2.	Itoh, Masatoshi: 2 articles (04/2004 - 05/2002)
3.	Murakami, Shinobu: 1 article (04/2008)
4.	Suzuki, Keiko: 1 article (04/2008)
5.	Takeyama, Sadaaki: 1 article (04/2008)
6.	Yamada, Shoji: 1 article (04/2008)
7.	Dannemann, C: 1 article (04/2007)
8.	Grätz, K W: 1 article (04/2007)
9.	Riener, M O: 1 article (04/2007)
10.	Zwahlen, R A: 1 article (04/2007)

Related Diseases

1.	Periodontitis 04/01/2008 - "The above results suggest that TRK-530 might be useful for the treatment of alveolar bone loss in periodontitis." 04/01/2007 - "Shinoda, A novel bisphosphonate, TRK-530, for periodontitis, Bone 38 (2006) 31-31; M. " 04/01/2008 - "To date, we have found that 1) TRK-530 inhibited osteoclastic bone resorption in animals and in bone organ culture, 2) both systemic and topical administration of TRK-530 prevented alveolar bone loss in animals with experimental periodontitis, 3) TRK-530 prevented prostaglandin E(2) synthesis by inhibiting the expression of cyclooxygenase (COX)-2 mRNA, and 4) TRK-530 inhibited the formation of dental calculus. "
2.	Alveolar Bone Loss 04/01/2008 - "The above results suggest that TRK-530 might be useful for the treatment of alveolar bone loss in periodontitis." 04/01/2008 - "To date, we have found that 1) TRK-530 inhibited osteoclastic bone resorption in animals and in bone organ culture, 2) both systemic and topical administration of TRK-530 prevented alveolar bone loss in animals with experimental periodontitis, 3) TRK-530 prevented prostaglandin E(2) synthesis by inhibiting the expression of cyclooxygenase (COX)-2 mRNA, and 4) TRK-530 inhibited the formation of dental calculus. "
3.	Experimental Arthritis 05/01/1998 - "We examined the anti-inflammatory effects of TRK-530 on adjuvant arthritis (AA) rats. " 05/01/1998 - "Inhibitory effects of TRK-530 on rat adjuvant arthritis." 11/01/1997 - "The effect of TRK-530 on experimental arthritis in mice." 05/01/1998 - "TRK-530 is a novel synthetic bisphosphonate compound which exhibits inhibitory activity in the rat adjuvant arthritis (AA) model. " 05/01/1998 - "Inhibitory effect of TRK-530 on inflammatory cytokines in bone marrow of rats with adjuvant arthritis."
4.	Edema (Dropsy) 05/01/1998 - "When TRK-530 at a dose of 2.5 mg/kg was administered for 2 weeks to AA rats, it inhibited destructive changes in arthritic joints such as paw edema, bone loss and joint degeneration. " 05/01/1998 - "Paw edema inhibition by TRK-530 in rat AA may be the result of decreasing CINC-1 and TNF-alpha concentrations."
5.	Dental Calculus 04/01/2004 - "TRK-530 inhibited the formation of dental calculus in a dose-dependent fashion via a local effect. " 04/01/2004 - "TRK-530 in drinking water inhibited dental calculus formation dose-dependently. " 04/01/2004 - "Inhibitory effect of a novel bisphosphonate, TRK-530, on dental calculus formation in rats." 04/01/2004 - "Since bisphosphonates have been shown to inhibit the formation of calcium-phosphate crystals in vitro, TRK-530 may inhibit the formation of dental calculus. " 04/01/2008 - "To date, we have found that 1) TRK-530 inhibited osteoclastic bone resorption in animals and in bone organ culture, 2) both systemic and topical administration of TRK-530 prevented alveolar bone loss in animals with experimental periodontitis, 3) TRK-530 prevented prostaglandin E(2) synthesis by inhibiting the expression of cyclooxygenase (COX)-2 mRNA, and 4) TRK-530 inhibited the formation of dental calculus. "

Related Drugs and Biologics

1.	Diphosphonates (Bisphosphonates)
2.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
3.	Drinking Water
4.	Collagen Type II (Type II Collagen)
5.	N-Acetylneuraminic Acid (Sialic Acid)
6.	Cytokines
7.	Superoxides (Superoxide)
8.	Messenger RNA (mRNA)
9.	Prostaglandins
10.	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)

Related Therapies and Procedures

1.	Topical Administration